108 related articles for article (PubMed ID: 10202231)
1. How should we evaluate new anti-infectives for respiratory tract infections?
Paladino JA
Can Respir J; 1999; 6 Suppl A():31A-4A. PubMed ID: 10202231
[TBL] [Abstract][Full Text] [Related]
2. A cost comparison of Canadian and U.S. hospital pharmacy departments.
Weil TP
Hosp Pharm; 1994 Jan; 29(1):15-7, 20-3. PubMed ID: 10131492
[TBL] [Abstract][Full Text] [Related]
3. Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy.
Lacroix A; Revest M; Patrat-Delon S; Lemaître F; Donal E; Lorléac'h A; Arvieux C; Michelet C; Tattevin P
Med Mal Infect; 2014 Jul; 44(7):327-30. PubMed ID: 25022891
[TBL] [Abstract][Full Text] [Related]
4. Incorporating pharmacoeconomic principles into hospital pharmacy practice.
Gouveia WA; Bungay KM
Top Hosp Pharm Manage; 1994 Jan; 13(4):31-7. PubMed ID: 10130681
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection.
Quenzer RW; Pettit KG; Arnold RJ; Kaniecki DJ
Am J Manag Care; 1997 Jul; 3(7):1027-36. PubMed ID: 10173367
[TBL] [Abstract][Full Text] [Related]
6. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs.
Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Land GA; Peterson LE; Musser JM
Arch Pathol Lab Med; 2013 Sep; 137(9):1247-54. PubMed ID: 23216247
[TBL] [Abstract][Full Text] [Related]
7. Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections.
Stein GE; Havlichek DH
Pharmacotherapy; 1997; 17(6):1139-47. PubMed ID: 9399598
[TBL] [Abstract][Full Text] [Related]
8. Costs of broad-spectrum antibiotic use for acute sinusitis, chronic bronchitis, and pneumonia in a managed care population.
Coughlin CM; Nelson M; Merchant S; Gondek K
Manag Care Interface; 2003 Jun; 16(6):34-40, 55. PubMed ID: 12841074
[TBL] [Abstract][Full Text] [Related]
9. Serving patient needs while implementing cost effectiveness programs in health care administration.
Tootelian DH
Health Mark Q; 1994; 11(3-4):161-73. PubMed ID: 10137013
[TBL] [Abstract][Full Text] [Related]
10. The cost of maintaining adequate antidote supplies.
Bailey B; Bussières JF
CMAJ; 2001 Nov; 165(11):1467. PubMed ID: 11762566
[No Abstract] [Full Text] [Related]
11. Streamlining antimicrobial therapy for lower respiratory tract infections.
Hitt CM; Nightingale CH; Quintiliani R; Nicolau DP
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S231-7. PubMed ID: 9126698
[TBL] [Abstract][Full Text] [Related]
12. [Clinical effectiveness and costs of antibiotics in respiratory infections].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2011 May; 30(179):327-9. PubMed ID: 21675134
[TBL] [Abstract][Full Text] [Related]
13. Cost-effective management of complicated urinary tract infections.
Cox CE
Adv Ther; 1995; 12(4):222-35. PubMed ID: 10155350
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic factors in the treatment of acute hypertension.
Shulkin DJ
Hosp Formul; 1994 Aug; 29 Suppl 2():S15-20. PubMed ID: 10135742
[TBL] [Abstract][Full Text] [Related]
15. Upper respiratory tract infections.
Adamovic L; Gricar JA; Cave DG
Manag Care Interface; 1999 Feb; 12(2):46-8, 53. PubMed ID: 10346185
[TBL] [Abstract][Full Text] [Related]
16. [Antibiotic pharmacoeconomics].
Jahnz-Rózyk K
Pol Merkur Lekarski; 2008 Nov; 25(149):437-8. PubMed ID: 19177784
[TBL] [Abstract][Full Text] [Related]
17. [Hospital essential drugs in Africa. An example of pharmacoeconomic research].
Meillon C; Stum N; Cuisinier-Raynal JC
Dakar Med; 1996; Spec No():19-20. PubMed ID: 14520980
[No Abstract] [Full Text] [Related]
18. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
19. Conducting pharmacoeconomic evaluations in a hospital setting.
Sanchez LA
Hosp Pharm; 1995 May; 30(5):412, 415-6, 428. PubMed ID: 10142378
[No Abstract] [Full Text] [Related]
20. Economic costs of respiratory tract infections in the United States.
Dixon RE
Am J Med; 1985 Jun; 78(6B):45-51. PubMed ID: 4014287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
